Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Portfolio Pulse from
Xenetic Biosciences, Inc. has extended its research agreement with the University of Virginia to advance its DNase-based oncology platform targeting neutrophil extracellular traps (NETs) through 2025. This extension aims to progress towards clinical proof-of-concept studies in multiple cancer indications.
December 16, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenetic Biosciences has extended its research agreement with the University of Virginia to further develop its DNase-based oncology platform, aiming for clinical proof-of-concept studies in multiple cancer indications.
The extension of the research agreement with UVA is a positive development for Xenetic Biosciences as it indicates continued progress and commitment to advancing their DNase-based oncology platform. This could lead to clinical proof-of-concept studies, potentially increasing investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100